---
title: "Sinobioway Medicine plans to sign a sales contract with Jiangsu Suhao, with a total contract price of 53.978 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231529652.md"
description: "Sinobioway Medicine's wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. plans to sign a sales contract with Jiangsu Suhao Innovation Technology Group Co., Ltd., with a total contract price of 53.978 million yuan, mainly for the procurement of equipment and materials needed for the biopharmaceutical industrial park project"
datetime: "2025-03-12T11:49:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231529652.md)
  - [en](https://longbridge.com/en/news/231529652.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231529652.md)
generator: "portal-rs"
---

# Sinobioway Medicine plans to sign a sales contract with Jiangsu Suhao, with a total contract price of 53.978 million yuan

According to the Zhitong Finance APP, Sinobioway Medicine (002581.SZ) announced that its wholly-owned subsidiary Shandong Yandu Biotechnology Co., Ltd. ("Shandong Yandu") plans to sign a "Sales Contract" with Jiangsu Suhao Innovation Technology Group Co., Ltd. ("Jiangsu Suhao") to procure the necessary 配储液系统 and chromatography systems, fillers, and reaction bags for the reconstruction of the human nerve growth factor eye drop production workshop at the Shandong Sinobioway Biomedical Industrial Park project, with a total contract price of 53.978 million yuan

### Related Stocks

- [002581.CN](https://longbridge.com/en/quote/002581.CN.md)
- [C76.SG](https://longbridge.com/en/quote/C76.SG.md)

## Related News & Research

- [RLO: Tripling revenue ambition, global defence focus, and innovation drive long-term growth](https://longbridge.com/en/news/297759336.md)
- [Teqnion agrees to acquire Scotland-based Abercromby Vending](https://longbridge.com/en/news/297759475.md)
- [Trump announces Medicaid drug pricing deals with 9 firms](https://longbridge.com/en/news/297557074.md)
- [SF Holding Reports Solid First Half 2026 Results, Accelerating International Growth and Enhancing Shareholder Returns](https://longbridge.com/en/news/297341511.md)
- [ANOT: Q2 2026 sales surged 64% year-over-year, but losses and liquidity risks persist](https://longbridge.com/en/news/297550756.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**